直肠癌临床实践指南（NCCN 肿瘤学版）2018 年第 2 版
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
出版信息
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, and survivorship in patients with rectal cancer. This portion of the guidelines focuses on the management of localized disease, which involves careful patient selection for curative-intent treatment options that sequence multimodality therapy usually comprised of chemotherapy, radiation, and surgical resection.
摘要
美国国家综合癌症网络（NCCN）肿瘤学临床实践指南（NCCN 指南）针对直肠癌的诊断、分期、手术治疗、围手术期治疗、复发性和转移性疾病的治疗、疾病监测以及直肠癌患者的生存问题提供了指导建议。本指南的这一部分重点关注局限性疾病的治疗管理，这需要对适合接受根治性治疗方案的患者进行仔细选择，这些方案通常包括化疗、放疗和手术切除的多模式治疗。
相似文献
1
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.直肠癌临床实践指南（NCCN 肿瘤学版）2018 年第 2 版
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.
2
Management of Locoregional Rectal Cancer.局部区域性直肠癌的治疗管理。
J Natl Compr Canc Netw. 2018 May;16(5S):617-619. doi: 10.6004/jnccn.2018.0037.
3
Evolving Treatment Paradigm in the Treatment of Locally Advanced Rectal Cancer.局部进展期直肠癌治疗模式的演变。
J Natl Compr Canc Netw. 2018 Jul;16(7):909-915. doi: 10.6004/jnccn.2018.7032.
4
Rectal Cancer in 2018: A Primer for the Gastroenterologist.2018 年直肠癌：胃肠病学家指南。
Am J Gastroenterol. 2018 Dec;113(12):1763-1771. doi: 10.1038/s41395-018-0180-y.
5
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.肛门癌临床实践指南 2018 年版 NCCN 肿瘤学
J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060.
6
Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).韩国结直肠外科学会（KSCP）新辅助同期放化疗后局部中低位进展期直肠癌巩固化疗的临床试验：一项多中心、随机对照试验（KONCLUDE）。
BMC Cancer. 2018 May 8;18(1):538. doi: 10.1186/s12885-018-4466-7.
7
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.霍奇金淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080.
8
Recommendations on Management of Locally Advanced Rectal Cancer During the COVID-19 Pandemic: an Iranian Consensus.2019冠状病毒病大流行期间局部晚期直肠癌管理的建议：伊朗共识
J Gastrointest Cancer. 2020 Sep;51(3):800-804. doi: 10.1007/s12029-020-00454-4.
9
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.NCCN 指南®洞察：直肠癌，第 3.2024 版。
J Natl Compr Canc Netw. 2024 Aug;22(6):366-375. doi: 10.6004/jnccn.2024.0041.
10
[Advances of optimized neoadjuvant therapy in the treatment of locally advanced rectal cancer].[优化新辅助治疗在局部晚期直肠癌治疗中的进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):527-533. doi: 10.3760/cma.j.issn.1671-0274.2019.06.005.
引用本文的文献
1
Is neoadjuvant immunotherapy feasible for patients with dMMR/MSI-H locally advanced colorectal cancer? a retrospective study.新辅助免疫疗法对错配修复缺陷/微卫星高度不稳定的局部晚期结直肠癌患者是否可行？一项回顾性研究。
Front Immunol. 2025 Aug 12;16:1645412. doi: 10.3389/fimmu.2025.1645412. eCollection 2025.
2
Lymph node morphology as an MRI biomarker for microsatellite instability in rectal cancer.淋巴结形态作为直肠癌微卫星不稳定性的MRI生物标志物
Abdom Radiol (NY). 2025 Aug 14. doi: 10.1007/s00261-025-05161-x.
3
Controversies and Perspectives in the Current Management of Patients with Locally Advanced Rectal Cancer-A Systematic Review.局部晚期直肠癌患者当前管理中的争议与展望——一项系统综述
Life (Basel). 2025 Jun 25;15(7):1011. doi: 10.3390/life15071011.
4
Baseline MRI habitat imaging for predicting treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.用于预测局部晚期直肠癌新辅助放化疗治疗反应的基线MRI栖息地成像
Front Oncol. 2025 Jul 11;15:1551224. doi: 10.3389/fonc.2025.1551224. eCollection 2025.
5
Log odds of positive lymph nodes-based staging system for colorectal cancer patients with inadequate lymph nodes harvested: a potential reference for adjuvant chemotherapy.淋巴结清扫不足的结直肠癌患者基于阳性淋巴结的分期系统的对数比值：辅助化疗的潜在参考
J Gastrointest Oncol. 2025 Jun 30;16(3):1038-1049. doi: 10.21037/jgo-2024-910. Epub 2025 Jun 16.
6
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study.新辅助放化疗联合信迪利单抗治疗PD-L1肿瘤比例评分（TPS）≥1%或综合阳性评分（CPS）≥1的错配修复功能完整/微卫星稳定的直肠癌患者：一项开放标签、前瞻性II期研究
NPJ Precis Oncol. 2025 Jul 12;9(1):237. doi: 10.1038/s41698-025-01018-0.
7
Narrative Review: Predictive Biomarkers of Tumor Response to Neoadjuvant Radiotherapy or Total Neoadjuvant Therapy of Locally Advanced Rectal Cancer Patients.叙述性综述：局部晚期直肠癌患者对新辅助放疗或全新辅助治疗反应的预测生物标志物
Cancers (Basel). 2025 Jul 3;17(13):2229. doi: 10.3390/cancers17132229.
8
A comparative study of machine learning models for predicting neoadjuvant chemoradiotheraphy response in rectal cancer patients using radiomics and clinical features.一项利用影像组学和临床特征预测直肠癌患者新辅助放化疗反应的机器学习模型的比较研究。
Medicine (Baltimore). 2025 Jul 4;104(27):e43173. doi: 10.1097/MD.0000000000043173.
9
Tuning vision foundation models for rectal cancer segmentation from CT scans.从CT扫描中调整用于直肠癌分割的视觉基础模型。
Commun Med (Lond). 2025 Jul 1;5(1):256. doi: 10.1038/s43856-025-00953-0.
10
A new way to remedy anastomotic leakage after TaTME: A case report.经肛全直肠系膜切除术（TaTME）后吻合口漏的一种新的补救方法：病例报告
Int J Surg Case Rep. 2025 Jul;132:111047. doi: 10.1016/j.ijscr.2025.111047. Epub 2025 Mar 18.
本文引用的文献
1
Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.新辅助放化疗后病理缓解对病理 III 期直肠癌预后的影响。
Ann Surg. 2019 Jun;269(6):1117-1123. doi: 10.1097/SLA.0000000000002719.
2
Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection.辅助化疗与新辅助化疗和切除术后病理完全缓解的直肠癌患者总生存的关系。
JAMA Oncol. 2018 Jul 1;4(7):938-943. doi: 10.1001/jamaoncol.2018.0231.
3
Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis.基于人群倾向评分分析，术前放化疗和手术后 ypTis-2N0 的直肠癌患者接受辅助化疗似乎没有生存获益。
Oncologist. 2019 Jun;24(6):803-811. doi: 10.1634/theoncologist.2017-0600. Epub 2018 Apr 19.
4
Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).局部晚期低危直肠癌术前放化疗联合帕尼单抗治疗的 II 期研究（RaP 研究/STAR-03）
Oncologist. 2018 Aug;23(8):912-918. doi: 10.1634/theoncologist.2017-0484. Epub 2018 Mar 9.
5
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
6
Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.直肠癌新辅助放化疗后肿瘤退缩分级作为无病生存的预后因素和个体水平替代指标。
J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx095.
7
Restaging Abdominopelvic Computed Tomography Before Surgery After Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.局部进展期直肠癌患者术前放化疗后手术前再次行全腹盆腔 CT 检查。
JAMA Oncol. 2018 Feb 1;4(2):259-262. doi: 10.1001/jamaoncol.2017.4596.
8
Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial.机器人辅助手术与传统腹腔镜手术对直肠癌切除患者中转开腹风险的影响：ROLARR随机临床试验
JAMA. 2017 Oct 24;318(16):1569-1580. doi: 10.1001/jama.2017.7219.
9
Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting.磁共振成像在直肠癌临床管理中的应用：2016 年欧洲胃肠道和腹部放射学会（ESGAR）共识会议的更新建议。
Eur Radiol. 2018 Apr;28(4):1465-1475. doi: 10.1007/s00330-017-5026-2. Epub 2017 Oct 17.
10
Outcomes of robotic versus laparoscopic surgery for mid and low rectal cancer after neoadjuvant chemoradiation therapy and the effect of learning curve.新辅助放化疗后机器人手术与腹腔镜手术治疗中低位直肠癌的疗效及学习曲线的影响
Medicine (Baltimore). 2017 Oct;96(40):e8171. doi: 10.1097/MD.0000000000008171.
Zotero 插件